Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Balingen – page 41

689 clinical trials in Balingen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Balingen at a glance
689
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

689 trials in Balingen

Open in trial search

Parkinson's disease

Not recruiting

Study on the Safety and Effects of Fasudil Hydrochloride for Patients with Parkinson's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fasudil Hydrochloride
  • Sponsor:Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)

Breast cancer+4

Not recruiting

Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Breast cancer

Not recruiting

Study on Trastuzumab Deruxtecan and Drug Combination for Patients with High-Risk HER2-Positive Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

Choroidal dystrophy+1

Not recruiting

Long-term Safety and Efficacy Study of Gene Therapy for Choroideremia and X-Linked Retinitis Pigmentosa Using AAV2-REP1 and AAV8-RPGR in Previously Treated Patients

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Timrepigene Emparvovec
  • Sponsor:Biogen Idec Research Limited

Study on Long-Term Safety and Efficacy of Cebsulfase Alfa for Children with Late Metachromatic Leukodystrophy Receiving Intrathecal Enzyme Replacement

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cebsulfase Alfa
  • Sponsor:Shire Human Genetic Therapies Inc.

Study on the Effect of Extending Imatinib Treatment from Three to Five Years for Patients with High-Risk Gastrointestinal Stromal Tumor (GIST)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Region Skane

Metastatic neoplasm+1

Not recruiting

Study on Treating Advanced Cancers with BRAF Mutations Using Sorafenib and Trametinib for Patients with Impaired Kinase Activity

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sorafenib
  • Sponsor:Medical Center - University Of Freiburg

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:Day One Biopharmaceuticals Inc.

Acoustic neuroma

Not recruiting

Study on Nimodipine for Hearing Preservation in Patients Undergoing Acoustic Schwannoma Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nimodipine
  • Sponsor:Martin-Luther-Universitaet Halle-Wittenberg

Study Comparing Tacrolimus Formulations for Preventing Liver Transplant Rejection in New Adult Recipients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Universitaetsklinikum Regensburg AöR

Renal cell carcinoma

Not recruiting

Study on Atezolizumab and Cabozantinib for Patients with Advanced Renal Cell Carcinoma After Tumor Progression Post-Immune Checkpoint Inhibitor Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.